We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. Treasury Attempts to Thwart Inversion Deals May Not Ruffle Pfizer-Allergan Deal
U.S. Treasury Attempts to Thwart Inversion Deals May Not Ruffle Pfizer-Allergan Deal
The U.S. Treasury Department says it is taking steps to curb tax-avoiding inversion deals, but there is little evidence to suggest it will halt the tie-up between New York-based Pfizer and Allergan that will see the former move its headquarters to Dublin.